Patients Harboring ALK Rearrangement Adenocarcinoma after Acquired Resistance to Crizotinib and Transformation to SCLC: A Case Report

被引：0

作者：

Wang, W. ^{[1
]}

Xu, C. ^{[2
]}

Zhu, Y. ^{[3
]}

Liao, X. ^{[4
]}

Zhuang, W. ^{[5
]}

Du, K. ^{[3
]}

Chen, R. ^{[6
]}

Chen, Y. ^{[2
]}

Chen, G. ^{[2
]}

Fang, M. ^{[1
]}

机构：

[1] Zhejiang Canc Hosp, Hangzhou, Zhejiang, Peoples R China

[2] Fujian Prov Canc Hosp, Pathol, Fuzhou, Fujian, Peoples R China

[3] Zhejiang Rongjun Hosp, Chest Dis Diag & Treatment Ctr, Jiaxing, Peoples R China

[4] Zhejiang Rongjun Hosp, Tumor Mol Lab, Jiaxing, Peoples R China

[5] Fujian Prov Canc Hosp, Med Oncol, Fuzhou, Fujian, Peoples R China

[6] Geneplus Beijing, Beijing, Peoples R China

来源：

关键词：

crizotinib; Resistance; small-cell lung cancer;

D O I：

10.1016/j.jtho.2017.09.1548

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P3.02-018

引用

页码：S2244 / S2244

页数：1